Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00144703 · ClinicalTrials.gov registry record · Phase 2
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT00144703 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 55 participants.
The verdict
NCT00144703, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the ability of sirolimus to prevent graft versus host disease (GVHD) in patients following stem cell transplant from a related donor.
Interventions
- DRUG Sirolimus
- DRUG Tacrolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2002-07 |
| Est. Completion | 2006-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00144703
The ClinicalTrials.gov registry entry for NCT00144703 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sirolimus is the first listed.
NCT00144703 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00144703 about?
NCT00144703 is a clinical study titled "Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation". The purpose of this study is to evaluate the ability of sirolimus to prevent graft versus host disease (GVHD) in patients following stem cell transplant from a related donor.
What is the current status of trial NCT00144703?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2002-07. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00144703?
The interventions under investigation include: Sirolimus (DRUG), Tacrolimus (DRUG).
Who is sponsoring clinical trial NCT00144703?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.